There are considerable gaps in the comparative effectiveness and tolerability of myo-inositol and metformin for treating obesity in patients with polycystic ovarian syndrome (PCOS). The current study aimed to give insights comparing myo-inositol versus metformin for treating obesity in patients with PCOS.
A review of the literature reveals inconsistent outcomes of myo-inositol vs metformin in the treatment of obesity and metabolic disorders in patients with PCOS, with comparable results and myo-inositol frequently demonstrating superior tolerability and reduced gastrointestinal side effects relative to metformin. When treating obesity in women with PCOS, practicing gynecologists would be able to select more appropriate medications by gathering data from local contexts. It will lessen psychological consequences associated with obesity, such as discrimination, stigma, low self-esteem, and poor quality of life.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Women were given tablet myo-inositol 1 gm twice a day for 3 months.
Women received metformin 250 mg three times daily for 3 months.
Bahwal Victoria Hospital
Bahawalpur, Punjab Province, Pakistan
Reduction in body mass index
A reduction in the body mass index with respect to baseline was taken as efficacy of the treatment.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.